AUA 2009 - Botulinum Toxin A (BOTOX®) Demonstrates Dose-Dependent Improvements in Health-Related Quality-of-Life Measures in Idiopathic Overactive Bladder - Poster
CHICAGO, IL, USA (UroToday.com) - This double-blind, placebo-controlled, Phase 2, dose-ranging study assessed the effects of BOTOX® treatment for patients with idiopathic OAB and UUI inadequately managed with anticholinergics.
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810
Privacy Policy | © 2009 UroToday ® All Rights Reserved |
